RVLP Projected Dividend Yield
Ord/RVL Pharmaceuticals plc ( NASDAQ : RVLP )RVL Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company focused on the development and commercialization of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Co.'s portfolio, RVL-1201, or Upneeq, (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy or low-lying eyelids in adults. Upneeq is a non-surgical treatment option for acquired blepharoptosis. Co.'s product candidate, arbaclofen extended release tablets, designed for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis. 20 YEAR PERFORMANCE RESULTS |
RVLP Dividend History Detail RVLP Dividend News RVLP Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |